LOTUSATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lotusate, and when can generic versions of Lotusate launch?
Lotusate is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in LOTUSATE is talbutal. Additional details are available on the talbutal profile page.
Summary for LOTUSATE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 19 |
Patent Applications: | 1,636 |
Formulation / Manufacturing: | see details |
DailyMed Link: | LOTUSATE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for LOTUSATE
US Patents and Regulatory Information for LOTUSATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | LOTUSATE | talbutal | TABLET;ORAL | 009410-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |